Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade D $3.10 0.00% 0.0
ACRX closed unchanged on Thursday, February 23, 2017, on 60 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Earnings due: Mar 2

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical ACRX trend table...

Date Alert Name Type % Chg
Feb 23 200 DMA Resistance Bearish 0.00%
Feb 23 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 22 Downside 200 DMA Break Bearish 0.00%
Feb 22 Narrow Range Bar Range Contraction 0.00%
Feb 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 21 Upside 200 DMA Break Bullish -1.59%
Feb 21 NR7 Range Contraction -1.59%
Feb 21 Narrow Range Bar Range Contraction -1.59%
Feb 17 200 DMA Resistance Bearish 0.00%
Feb 17 Stochastic Reached Overbought Other 0.00%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company’s principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. In addition, the company’s product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.5
52 Week Low 2.4
Average Volume 219,320
200-Day Moving Average 3.12
50-Day Moving Average 2.82
20-Day Moving Average 2.95
10-Day Moving Average 3.1
Average True Range 0.15
ADX 20.8
+DI 23.96
-DI: 18.75
Chandelier Exit (Long, 3 ATRs) 2.8
Chandelier Exit (Short, 3 ATRs) 3.0
Upper Bollinger Band 3.37
Lower Bollinger Band 2.53
Percent B (%b) 0.68
Bandwidth 0.284746